Description: Capricor Therapeutics, Inc., a biotechnology company, is focused on the development of novel therapeutics to prevent and treat cardiovascular diseases. Its lead product candidates include CAP-1002 and Cenderitide. The company was founded in 2005 and is based in Beverly Hills, California.
Home Page: www.capricor.com
CAPR Technical Analysis
10865 Road to the Cure
San Diego,
CA
92121
United States
Phone:
310 358 3200
Officers
| Name | Title |
|---|---|
| Dr. Frank Isaac Litvack FACC, M.D. | Exec. Chairman |
| Dr. Linda Marbán Ph.D. | Co-Founder, Pres, CEO & Director |
| Mr. Anthony J. Bergmann M.B.A. | CFO & Corp. Treasurer |
| Ms. Karen G. Krasney | Exec. VP, Gen. Counsel & Sec. |
| Dr. Eduardo Marbán | Co-Founder & Chairman of Scientific Advisory Board |
| Mr. Xavier Avat | Chief Bus. Officer |
| Dr. Deborah D. Ascheim | Consultant |
| Catherine Lee Kelleher | Consultant |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 6.4959 |
| Price-to-Sales TTM: | 61.6934 |
| IPO Date: | 2007-02-13 |
| Fiscal Year End: | December |
| Full Time Employees: | 48 |